Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Ratio (2021 - 2025)

Historic Equity Ratio for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 0.87.

  • InMed Pharmaceuticals' Equity Ratio rose 813.47% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year increase of 813.47%. This contributed to the annual value of 0.86 for FY2025, which is 1073.79% up from last year.
  • InMed Pharmaceuticals' Equity Ratio amounted to 0.87 in Q3 2025, which was up 813.47% from 0.86 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Equity Ratio peaked at 0.88 during Q3 2021, and registered a low of 0.88 during Q3 2023.
  • For the 5-year period, InMed Pharmaceuticals' Equity Ratio averaged around 0.7, with its median value being 0.8 (2024).
  • Its Equity Ratio has fluctuated over the past 5 years, first crashed by 21623.65% in 2023, then soared by 19144.04% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Equity Ratio stood at 0.73 in 2021, then rose by 15.92% to 0.85 in 2022, then fell by 1.18% to 0.84 in 2023, then dropped by 13.15% to 0.73 in 2024, then rose by 19.31% to 0.87 in 2025.
  • Its last three reported values are 0.87 in Q3 2025, 0.86 for Q2 2025, and 0.76 during Q1 2025.